Iovance owns more than 25 U.S. patents related to TIL therapy, including patents directed to compositions and methods of treatment in a broad range of cancers, such as U.S. Patent Nos. 10,894,063; 10,517,894; 10,166,257; 10,130,659; 10,272,113; 10,420,799; 10,398,734; 10,537,595; 10,639,330; 10,463,697; 10,363,273; 10,695,372; 10,646,517; 10,653,723; 10,905,718; 10,953,046; 10,946,044; 10,953,047; 10,933,094; 10,946,045; 10,925,900; 10,918,666; 11,007,225; 11,007,226; 11,013,770; 11,026,974; 11,040,070; 11,052,115; 11,052,116; and 11,058,728.
Iovance also owns U.S. patents covering TIL manufactured from a tumor digest and the use thereof, such as U.S. Patent Nos. 11,007,225; 11,007,226; 11,052,115; 11,052,116; and 11,058,728; and others.
U.S. Pat. No. 11,058,728 specifically covers a method of treatment using expanded TILs manufactured from a tumor digest where the steps of expansion to cryopreservation of the infusion bag having a harvested TIL population include two expansion steps in which the second expansion step is performed within about 14 days.
Furthermore, Iovance owns U.S. patents covering the use of the combination of TIL and an anti-PD-1 antibody, such as U.S. Patent No. 10,272,113, or an anti-PD-L1 antibody, such as U.S. Patent No. 11,013,770.
